Why Farbe Firma is the Top Manufacturer of Quinine Dihydrochloride Injection
- Maulik Sudani
- 14 minutes ago
- 6 min read
Last Updated: May 23, 2026
TL;DR: Quinine Dihydrochloride Injection — quinine dihydrochloride, a cinchona-alkaloid blood schizonticide supplied as a clear sterile aqueous solution in light-protected ampoules — remains the WHO-listed parenteral antimalarial that clinicians depend on to treat severe and complicated Plasmodium falciparum malaria, particularly where injectable artesunate is unavailable. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Quinine Dihydrochloride Injection at our Gujarat, India facility and supplies it to hospital tenders, national malaria-control programmes, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Antimalarial cinchona alkaloid — a rapid-acting blood schizonticide active against Plasmodium falciparum, including chloroquine-resistant strains. A WHO Essential Medicine and a frontline parenteral therapy for severe and complicated malaria when injectable artesunate is unavailable.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule filling lines with nitrogen purging, tight acidic pH control and validated terminal moist-heat sterilisation with full container-closure integrity verification.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets.
End-to-end CMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Quinine Dihydrochloride Injection Demands a Premium Manufacturer
Quinine Dihydrochloride Injection occupies a place few medicines do: it is a centuries-old cinchona alkaloid that still saves lives in the twenty-first century. When a patient presents with severe or complicated falciparum malaria — impaired consciousness, convulsions, severe anaemia, acidosis or high parasitaemia — the parasite has to be cleared from the bloodstream fast, and parenteral quinine remains a WHO-recommended option where injectable artesunate is out of stock or unsuitable. In malaria-endemic districts of sub-Saharan Africa and Southeast Asia, a reliable supply of Quinine Dihydrochloride Injection is not a procurement line item; it is the difference between a manageable admission and a preventable death.
That clinical weight places exacting demands on the manufacturer. Quinine is administered by slow, rate-controlled intravenous infusion because rapid delivery risks cardiotoxicity, hypotension and dangerous hypoglycaemia — so every ampoule must carry an accurate, uniform dose, commonly 300 mg/mL of quinine dihydrochloride in 1 mL and 2 mL presentations. The alkaloid is also photosensitive and is formulated as an acidic aqueous solution, which means light-protected processing, tight pH control and a validated terminal sterilisation cycle are all non-negotiable. Choosing a Quinine Dihydrochloride Injection manufacturer that treats dose uniformity, photostability and ampoule integrity as core engineering disciplines is what keeps a life-saving antimalarial supply chain dependable.
What Sets a World-Class Quinine Dihydrochloride Injection Manufacturer Apart
A world-class manufacturer of Quinine Dihydrochloride Injection invests in three areas that weaker suppliers underfund: precision alkaloid formulation, light- and oxygen-controlled processing, and a stability programme built for tropical distribution. Precision formulation means validated dissolution of the bitter, highly water-soluble dihydrochloride salt into large solution batches, in-process assay at multiple points, controlled fill-weight checks across the entire run, and content-uniformity verification so the first and last ampoule of a batch deliver the same accurate dose. For a drug infused by weight-based dosing in a critically ill patient, that consistency is non-negotiable.
Light- and oxygen-controlled processing matters because quinine is a photolabile cinchona alkaloid. World-class plants compound the bulk solution under nitrogen blanket, hold and verify pH within the narrow acidic band where quinine is most stable, minimise the time bulk product spends warm or exposed to light, and validate the moist-heat sterilisation cycle so the lethality delivered to microorganisms does not come at the cost of unacceptable alkaloid degradation. ICH Q1B photostability testing confirms the chosen amber ampoule and carton protect the product across its shelf life. All of this is captured in electronic batch records that lock deviations the moment they occur, and reinforced by 100% ampoule leak and integrity inspection from filling through final packaging.
Quality Systems Behind Every Quinine Dihydrochloride Injection
Every Farbe Firma Quinine Dihydrochloride Injection batch is released only after a full stack of quality checks: identity and assay by validated stability-indicating HPLC against USP, BP, IP or EP reference standards, related-substances profiling to keep cinchona-alkaloid impurities such as dihydroquinine within monograph limits, pH, particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and content-uniformity testing appropriate to a weight-dosed parenteral. Certificates of analysis are issued with full traceability back to API lot, excipient lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal moist-heat cycles with load mapping, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — alongside ICH Q1B photostability data, so we can assure customers the Quinine Dihydrochloride Injection they buy today will still meet specification when it reaches the patient months later in a hot, humid climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Quinine Dihydrochloride Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across antimalarial, anti-infective, emergency-medicine, anaesthesia and critical-care categories. For Quinine Dihydrochloride Injection specifically, we supply the 300 mg/mL strength in 1 mL and 2 mL ampoule presentations as standard, with custom strengths, fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market — including the photostability data that malaria-programme regulators increasingly expect.
Our CDMO services scale cleanly from hospital pharmacy supply to full national malaria-control tender procurement. We prepare full eCTD and ACTD modules, drug master files, ICH Q1A and Q1B stability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Quinine Dihydrochloride Injection on a tight deadline — and antimalarial stock often is urgent ahead of a transmission season — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with one accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through formulation, pH control, photostability strategy, sterilisation design, container-closure and stability choices in real detail. For an antimalarial parenteral where dose accuracy and sterility decide patient outcomes, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Quinine Dihydrochloride Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Quinine Dihydrochloride Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule filling lines, qualified water-for-injection systems and validated environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Quinine Dihydrochloride Injection do you supply?
Our standard presentation is quinine dihydrochloride 300 mg/mL as a clear sterile solution in 1 mL and 2 mL light-protected ampoules for slow intravenous infusion. Custom strengths, fill volumes, vial formats and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Quinine Dihydrochloride Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages, ICH Q1B photostability data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma protect Quinine Dihydrochloride Injection from light degradation?
Quinine is a photosensitive cinchona alkaloid, so the bulk solution is compounded under nitrogen blanket, the pH is adjusted and verified within quinine's narrow acidic stability window, and product is staged under light-protected conditions through filling and packaging. ICH Q1B photostability testing confirms the amber ampoule and carton protect the product, and cinchona-alkaloid impurities are monitored on every batch by validated stability-indicating HPLC against monograph limits.
What is the minimum order quantity for Quinine Dihydrochloride Injection contract manufacturing?
MOQs vary by strength, label complexity and dossier requirements. For the standard 300 mg/mL ampoule presentation we accommodate hospital-scale and full malaria-control-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments